Skip to main content

Table 3 ORs (95% CIs) for a 30% baseline biomarker increment from analyses that include data from both WHI postmenopausal HT trials

From: Proteomic risk markers for coronary heart disease and stroke: validation and mediation of randomized trial hormone therapy effects on these diseases

CHD
  B2M ORM1 THBS1 CFD IGFBP1
Baseline biomarker 1.21 (1.09, 1.35)a,c 1.01 (0.89, 1.14) 0.97 (0.93, 1.00) 1.16 (1.03, 1.31)c 1.03 (0.99, 1.08)
Treatmentb 1.32 (0.97, 1.81) 1.33 (0.97, 1.81) 1.34 (0.96, 1.87) 1.31 (0.95, 1.78) 1.29 (0.94, 1.77)
Trialb 1.13 (0.82, 1.56) 1.09 (0.79, 1.51) 1.02 (0.72, 1.44) 1.09 (0.79, 1.50) 1.05 (0.76, 1.47)
Stroke
  B2M IGFBP2 IGFBP4 IGFBP6 HPX
Baseline biomarker 1.18 (1.04, 1.34)a,c 1.10 (1.03, 1.18)c 1.16 (1.04, 1.28)c 1.01 (0.94, 1.09) 1.10 (0.95, 1.27)
Treatmentb 1.90 (1.38, 2.62) 1.77 (1.27, 2.46) 1.76 (1.21, 2.54) 1.70 (1.22, 2.38) 1.79 (1.30, 2.48)
Trialb 1.09 (0.79, 1.50) 1.10 (0.79, 1.53) 1.09 (0.75, 1.59) 1.11 (0.79, 1.55) 1.13 (0.81, 1.56)
  1. aAll analyses also include baseline age, prior history of study disease, systolic and diastolic blood pressure, smoking history, treated diabetes history, prior HT use, and body mass index as regression variables to control confounding.
  2. bTreatment, 1 - active; 0 - placebo; Trial, 1 - E + P trial (no hysterectomy), 0 - E-alone trial (post-hysterectomy).
  3. cSignificant at P = 0.05.
Back to article page

Genome Medicine

ISSN: 1756-994X

Contact us